Evidence map›Paper›PMID 39470202›Full record

ArticleAntimicrobial agents and chemotherapy2024

TBAJ-587, a novel diarylquinoline, is active against

Junsheng Fan, Zhili Tan, Siyuan He, Anqi Li, Yaping Jia, Juan Li, Zhemin Zhang, Bing Li, Haiqing Chu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Frontiers in microbiology · 2026
    Article
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Junsheng Fan *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-5143-2968
Zhili Tan *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Siyuan He *Department of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Anqi LiDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Yaping JiaDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Juan LiDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Zhemin ZhangDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.
Bing LiDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0003-0234-044X
Haiqing ChuDepartment of Respiratory and Critical Care Medicine, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China.ORCID 0000-0002-9168-7295

Funding

Clinical Research foundation of Shanghai Pulmonary Hospital FKLY20009MOST | National Natural Science Foundation of China (NSFC) 81672063,81971973MOST | National Natural Science Foundation of China (NSFC) 82270005,81800003STCSM | Natural Science Foundation of Shanghai Municipality () 20ZR1447200STCSM | Natural Science Foundation of Shanghai Municipality () 21ZR1453600STCSM | Natural Science Foundation of Shanghai Municipality () 22ZR1452000STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission () 21Y11900700STCSM | Science and Technology Innovation Plan Of Shanghai Science and Technology Commission () 23S11901400
6 · The paper itself

Abstract

Nontuberculous mycobacteria (NTM) infections are extremely difficult to treat due to a natural resistance to many antimicrobials. TBAJ-587 is a novel diarylquinoline, which shows higher anti-tuberculosis activity, lower lipophilicity, and weaker inhibition of hERG channels than bedaquiline (BDQ). The susceptibilities of 11 NTM reference strains and 194 clinical

Indexed as

DiarylquinolinesMicrobial Sensitivity TestsMycobacterium abscessusMycobacterium Infections, NontuberculousAnimalsAnti-Bacterial AgentsAntitubercular AgentsDrug SynergismHumansMacrophagesMiceQuinolinesAnti-Bacterial AgentsAntitubercular AgentsbedaquilineDiarylquinolinesQuinolinesdiarylquinolineMycobacterium abscessusnontuberculous mycobacteriaTBAJ-587

Identifiers

PMID39470202
PMCPMC11619292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.